Opioid use is increasing, and not just for chronic conditions or cancer
Global concern about the prescribing of opioid analgesic medications (particularly oxycodone) for chronic pain is growing. In this Journal in September 2011, Roxburgh and colleagues examined the rise of oxycodone and morphine prescribing and the harm associated with opioid use.1 In the accompanying editorial, Hall and Farrell argued that this suggests that most prescribing of opioids was for chronic non-malignant pain.2 We tested this assertion using general practitioner prescribing data linked to the problem under management, and examined the characteristics of the GPs who prescribed opioids and the patients who received these prescriptions.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We thank the GP participants in BEACH and all members of the BEACH team. During the data collection years reported here, the BEACH program was funded by the Australian Government Department of Health and Ageing, the Australian Institute of Health and Welfare, the National Prescribing Service, AstraZeneca Australia, Roche Products, Janssen-Cilag, Merck Sharp and Dohme (Australia), Pfizer Australia, Sanofi-Aventis Australia, Abbott Australasia, Wyeth Australia, CSL Limited, GlaxoSmithKline Australia, Australian Government Department of Veterans’ Affairs and the Office of the Australian Safety and Compensation Council (Australian Government Department of Employment and Workplace Relations).
No relevant disclosures.